Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy

  • Caño-Ochoa, Francisco del
  • Ng, Bobby G.
  • Abedalthagafi, Malak
  • Almannai, Mohammed
  • Cohn, Ronald D.
  • Costain, Gregory
  • Elpeleg, Orly
  • Houlden, Henry
  • Karimiani, Ehsan Ghayoor
  • Liu, Pengfei
  • Manzini, M Chiara
  • Maroofian, Reza
  • Muriello, Michael
  • Al-Otaibi, Ali
  • Patel, Hema
  • Shimon, Edvardson
  • Sutton, V. Reid
  • Toosi, Mehran Beiraghi
  • Wolfe, Lynne A.
  • Rosenfeld, Jill A.
  • Freeze, Hudson H.
  • Ramón-Maiques, Santiago
8 pages, 4 figures, 1 table. The online version of this article (https://doi.org/10.1038/s41436-020-0833-2) contains supplementary material, which is available to authorized users., Purpose: Pathogenic autosomal recessive variants in CAD, encoding the multienzymatic protein initiating pyrimidine de novo biosynthesis, cause a severe inborn metabolic disorder treatable with a dietary supplement of uridine. This condition is difficult to diagnose given the large size of CAD with over 1000 missense variants and the nonspecific clinical presentation. We aimed to develop a reliable and discerning assay to assess the pathogenicity of CAD variants and to select affected individuals that might benefit from uridine therapy. Methods: Using CRISPR/Cas9, we generated a human CAD-knockout cell line that requires uridine supplements for survival. Transient transfection of the knockout cells with recombinant CAD restores growth in absence of uridine. This system determines missense variants that inactivate CAD and do not rescue the growth phenotype. Results: We identified 25 individuals with biallelic variants in CAD and a phenotype consistent with a CAD deficit. We used the CAD-knockout complementation assay to test a total of 34 variants, identifying 16 as deleterious for CAD activity. Combination of these pathogenic variants confirmed 11 subjects with a CAD deficit, for whom we describe the clinical phenotype. Conclusions: We designed a cell-based assay to test the pathogenicity of CAD variants, identifying 11 CAD-deficient individuals who could benefit from uridine therapy., This work was supported by The Rocket Fund, by R01DK99551 to H.H.F., and by grants BFU2016–80570-R and RTI2018–098084- B-100 from the Spanish Ministry of Science and Innovation (AEI/ FEDER, UE) and with partial support from U54 NS115198. The University of Washington Center for Mendelian Genomics for exome sequencing and analysis of CDG-0117, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mechanisms of feedback inhibition and sequential firing of active sites in plant aspartate transcarbamoylase

  • Bellin, Leo
  • Caño-Ochoa, Francisco del
  • Velázquez-Campoy, Adrián
  • Möhlmann, Torsten
  • Ramón-Maiques, Santiago
13 páginas, 6 figuras., Aspartate transcarbamoylase (ATC), an essential enzyme for de novo pyrimidine biosynthesis, is uniquely regulated in plants by feedback inhibition of uridine 5-monophosphate (UMP). Despite its importance in plant growth, the structure of this UMP-controlled ATC and the regulatory mechanism remain unknown. Here, we report the crystal structures of Arabidopsis ATC trimer free and bound to UMP, complexed to a transition-state analog or bearing a mutation that turns the enzyme insensitive to UMP. We found that UMP binds and blocks the ATC active site, directly competing with the binding of the substrates. We also prove that UMP recognition relies on a loop exclusively conserved in plants that is also responsible for the sequential firing of the active sites. In this work, we describe unique regulatory and catalytic properties of plant ATCs that could be exploited to modulate de novo pyrimidine synthesis and plant growth., This work was supported by funding from the Spanish Ministry of Science, Innovation and Universities (BFU2016-80570-R and RTI2018-098084-B-100; AEI/FEDER, UE) to S.R.-M., DFG (Mo 1032/4-1 and CRC175-B08) to T.M., DFG-IRTG 1830 to T.M. and L.B., and Bayer AG Crop Science (Grants for Targets 2017-02-005) to S.R.-M. and T.M. We thank the staff from ALBA (Barcelona, Spain) and ESRF (Grenoble, France) synchrotron facilities for help during crystallographic data collection; R. Campos-Olivas and C.M. Santiveri for support with SEC-MALS analyses; S. Niopek-Witz and N. Navaseelan for support with ATC expression and kinetic analysis; L. Ohler, A. John, and A. Grande-García for support during protein purification, mutant generation, and crystallization trials; and M. Moreno-Morcillo for support with crystal structure analysis., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Deciphering CAD: Structure and function of a mega-enzymatic pyrimidine factory in health and disease

  • Caño-Ochoa, Francisco del
  • Ramón-Maiques, Santiago
14 páginas, 6 figuras, 1 tabla., CAD is a 1.5 MDa particle formed by hexameric association of a 250 kDa protein divided into different enzymatic domains, each catalyzing one of the initial reactions for de novo biosynthesis of pyrimidine nucleotides: glutaminase-dependent Carbamoyl phosphate synthetase, Aspartate transcarbamoylase, and Dihydroorotase. The pathway for de novo pyrimidine synthesis is essential for cell proliferation and is conserved in all living organisms, but the covalent linkage of the first enzymatic activities into a multienzymatic CAD particle is unique to animals. In other organisms, these enzymatic activities are encoded as monofunctional proteins for which there is abundant structural and biochemical information. However, the knowledge about CAD is scarce and fragmented. Understanding CAD requires not only to determine the three-dimensional structures and define the catalytic and regulatory mechanisms of the different enzymatic domains, but also to comprehend how these domains entangle and work in a coordinated and regulated manner. This review summarizes significant progress over the past 10 years toward the characterization of CAD's architecture, function, regulatory mechanisms, and cellular compartmentalization, as well as the recent finding of a new and rare neurometabolic disorder caused by defects in CAD activities., Fundación Ramón Areces, Grant/AwardNumber: XX National Call; area of RareDiseases; Ministerio de Ciencia eInnovación, Grant/Award Number:RTI2018-098084-B-100; AEI/FEDER; UE, Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Mechanisms of feedback inhibition and sequential firing of active sites in plant aspartate transcarbamoylase

  • Bellin, L.
  • Del Caño-Ochoa, F.
  • Velázquez-Campoy, A.
  • Möhlmann, T.
  • Ramón-Maiques, S.
Aspartate transcarbamoylase (ATC), an essential enzyme for de novo pyrimidine biosynthesis, is uniquely regulated in plants by feedback inhibition of uridine 5-monophosphate (UMP). Despite its importance in plant growth, the structure of this UMP-controlled ATC and the regulatory mechanism remain unknown. Here, we report the crystal structures of Arabidopsis ATC trimer free and bound to UMP, complexed to a transition-state analog or bearing a mutation that turns the enzyme insensitive to UMP. We found that UMP binds and blocks the ATC active site, directly competing with the binding of the substrates. We also prove that UMP recognition relies on a loop exclusively conserved in plants that is also responsible for the sequential firing of the active sites. In this work, we describe unique regulatory and catalytic properties of plant ATCs that could be exploited to modulate de novo pyrimidine synthesis and plant growth.